University Health System

Bio Products Laboratory | May 29, 2020

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, today announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection, with supply immediately available. ALBUMINEX 5% and ALBUMINEX 25% are approved by the US Food and Drug Administration for the treatment of hypovole...

Medical Devices, Healthcare Analytics

Globenewswire | May 09, 2023

LifeMD, Inc. a leading provider of virtual primary care services, today announced that it has entered into an agreement to be the exclusive telehealth provider for HealthWarehouse.com, Inc. The partnership between the two companies will enable HealthWarehouse.com to offer virtual treatment to over one million existing patients and make available real-time consultations to potential new patients purchasing pharmacy products from their online health marketplace. LifeMD’s 50-...

Health Technology

Netsmart | September 23, 2022

Netsmart, the developer of the industry-leading CareFabric® platform for human services, post-acute care providers and payers announced its intent to apply to join the Trusted Exchange Framework and Common Agreement to become a Qualified Health Information Network. By supporting TEFCA, Netsmart continues its decade-long advancement of interoperability strategies to facilitate an open exchange of longitudinal healthcare data that will benefit individuals receiving care across the healthcar...

MedCity News | January 15, 2020

Although it faced a setback earlier this month when regulators put the kibosh on its deal to acquire a rival company, genetic sequencing equipment maker Illumina will leave the J.P. Morgan Healthcare Conference with two new partnering deals under its belt. The San Diego-based company and Swiss drug and diagnostics maker Roche said Monday that they had formed a partnership to increase availability of genomic testing to patients with cancers. The 15-year, non-exclusive partnership is meant to broa...